

Oxaliplatin

Chemical Properties

CAS No. : 61825-94-3

Formula: C₈H₁₄N₂O₄Pt



Molecular Weight: 397.29

Storage:

Keep away from direct sunlight, The compound is unstable in solution. Please use soon

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Oxaliplatin (L-OHP) is a DNA alkylating agent and DNA synthesis inhibitor. Oxaliplatin induces cellular autophagy and DNA cross-linking damage, thereby inhibiting DNA replication and transcription and leading to cell death. Oxaliplatin is unstable in chlorine-containing systems; dissolution in saline or PBS is not recommended. A 5% glucose/dextrose solution can be used to prepare the solution for in vivo administration.
Targets(IC50)	Apoptosis, Autophagy, DNA Alkylator/Crosslinker, DNA/RNA Synthesis
In vitro	<p>METHODS: Human colon cancer cells HT29, SW620, WiDr and LS174T were treated with Oxaliplatin (0.001 ng/ml-100 µg/mL) for 24 h, and cytotoxicity was detected using MTT method.</p> <p>RESULTS: Oxaliplatin was cytotoxic to HT29, SW620, WiDr and LS174T cells, with IC₅₀s of 0.33, 1.13, 0.13 and 0.19 µg/mL, respectively. [1]</p> <p>METHODS: Human colon cancer cells HCT116 WT and CHK2 KO were treated with Oxaliplatin (40 µM) for 24-96 h. Apoptosis was detected by Flow Cytometry.</p> <p>RESULTS: Oxaliplatin treatment for 24-96 h increased apoptosis levels in WT and CHK2-KO cell lines. From 24-72 h, the apoptosis level of WT cells was consistently twofold lower than that of CHK2 KO cells. However, treatment for 96 h resulted in the same level of apoptosis in WT and CHK2-KO cells (85%). [2]</p> <p>METHODS: Human oral squamous cell carcinoma cells CAL27 and SCC25 were treated with Oxaliplatin (31.25-125 µM) and Oxaliplatin (25-100 µM) for 12-36 h. Cell migration was detected using the Wound-healing method.</p> <p>RESULTS: Oxaliplatin inhibited the migration of CAL27 and SCC25 cells in a dose-dependent manner. [3]</p>
In vivo	<p>METHODS: To detect anti-tumor activity in vivo, Oxaliplatin (5 mg/kg) and piperlongumine (2.5 mg/kg) were administered intraperitoneally once a day for twenty-four days to BALB/c nu/nu mice bearing human colorectal carcinoma tumor HCT-116.</p> <p>RESULTS: The combination of Oxaliplatin and piperlongumine significantly inhibited tumor growth, and piperlongumine sensitized tumors to Oxaliplatin through ROS-mediated apoptosis in vivo. [4]</p> <p>METHODS: To model platinum-induced painful peripheral neuropathy, Oxaliplatin (3 mg/kg/day) was injected intraperitoneally into C57BL6j mice for five days with five days of rest for two cycles.</p>

In vivo	RESULTS: Mice in the Oxaliplatin-treated group exhibited significant mechanical anomalous pain. the Oxaliplatin group exhibited significant cold nociceptive hypersensitivity in the hindfoot. [5]
Kinase Assay	Binding experiments of electrophysiology: CHO cells expressing the subunit of the voltage-dependent L-type Ca ²⁺ channel are cultured in medium without serum in the presence of different concentrations of Nisoldipine. Then Ca ²⁺ channel current elicited from a holding potential of -100 mV or -50 mV is recorded at room temperature with the whole-cell configuration of the patch-clamp method using the List EPC-7 patch-clamp amplifier and pClamp software. The concentration of competitor inhibiting 50% of the specific binding represents IC ₅₀ .
Cell Research	The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetric assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO ₂ and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 10 ³ cells/50 μL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control(Only for Reference)

Solubility Information

Solubility	Ethanol: < 1 mg/mL (insoluble) DMSO: 50 mg/mL (125.85 mM),DMSO inactivates the activity of Oxaliplatin. H ₂ O: 2.5 mg/mL (6.29 mM),Sonication is recommended. DMF: 1.67 mg/mL (4.2 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5171 mL	12.5853 mL	25.1705 mL
5 mM	0.5034 mL	2.5171 mL	5.0341 mL
10 mM	0.2517 mL	1.2585 mL	2.5171 mL
50 mM	0.0503 mL	0.2517 mL	0.5034 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Nannizzi S, et al. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. *Cancer Chemother Pharmacol*. 2010 Aug;66(3):547-58.
- Chao S, Zhang F, Yan H, et al. Targeting intratumor heterogeneity suppresses colorectal cancer chemoresistance and metastasis. *EMBO reports*. 2023: e56416.
- Glorieux C, Xia X, You X, et al. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. *Journal of Advanced Research*. 2021
- Huang Y, Wang H, Hao Y, et al. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity[J]. *Nature Cell Biology*. 2020: 1-12. (22-6, 716-727)
- Huang Y, Wang H, Hao Y, et al. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. *Nature Cell Biology*. 2020: 1-12. (22-6, 716-727)
- Wang X, Wu F, Wang H, et al. PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation. *Journal of Experimental & Clinical Cancer Research*. 2020, 39(1): 1-15
- Zhou Y, Yang L, Xiong L, et al. KIF11 is upregulated in colorectal cancer and silencing of it impairs tumor growth and sensitizes colorectal cancer cells to oxaliplatin via p53/GSK3 β signaling. *Journal of Cancer*. 2021, 12(12): 3741.
- Lee E J, Yang J H, Choi J G, et al. Augmented Antitumor Effect of Unripe *Rubus coreanus* Miquel Combined with Oxaliplatin in a Humanized PD-1/PD-L1 Knock-In Colorectal Cancer Mouse Model. *Cells*. 2022, 11(18): 2876.
- Lin W, Zou H, Mo J, et al. Micro1278 Leads to Tumor Growth Arrest, Enhanced Sensitivity to Oxaliplatin and Vitamin D and Inhibits Metastasis via KIF5B, CYP24A1, and BTG2, Respectively. *Frontiers in Oncology*. 2021 Mar 11;11: 637878. doi: 10.3389/fonc.2021.637878. eCollection 2021.
- Shen X, Zhang Y, Xu Z, et al. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response. *Cell Death & Disease*. 2022, 13(4): 1-13
- Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation. *Journal of chemical information and modeling*. 2019, 59(10): 4374-4382.
- Yang P, Liu W, Fu R, et al. Cucurbitacin E Chemosensitizes Colorectal Cancer Cells via Mitigating TFAP4/Wnt/ β -Catenin Signaling. *Journal of Agricultural and Food Chemistry*. 2020 Nov 18. doi: 10.1021
- Bi G, Liang J, Zhao M, et al. MiR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma by targeting CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways. *Molecular Therapy-Nucleic Acids*. 2022
- Pires IM, et al. Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. *Br J Pharmacol*. 2010 Mar;159(6):1326-38.
- Jiang Y, Feng Y, Huang J, et al. LAD1 promotes malignant progression by diminishing ubiquitin-dependent degradation of vimentin in gastric cancer. *Journal of Translational Medicine*. 2023, 21(1): 1-15.
- Qiao S, Lu W, Glorieux C, et al. Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer. *Oncogene*. 2021: 1-13.
- Su C, Cheng C, Rong Z, et al. Repurposing fluphenazine as an autophagy modulator for treating liver cancer. *Heliyon*. 2023
- Lee E J, Kim Y S, Kim J H, et al. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (*Oenothera biennis*) root extract and its active compound oenotherin B targeting the PD-1/PD-L1 blockade. *Phytomedicine*. 2024: 155370.
- Hu H F, Han L, Fu J Y, et al. LINC00982-encoded protein PRDM16-DT regulates CHEK2 splicing to suppress colorectal cancer metastasis and chemoresistance. *Theranostics*. 2024, 14(8): 3317.
- Wu T, Yu Y, Tu X, et al. Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer. *Journal of Ethnopharmacology*. 2024: 118754.
- Zhao X, Zhao Z, Li B, et al. ACSL4-mediated lipid rafts prevent membrane rupture and inhibit immunogenic cell death in melanoma. *Cell Death & Disease*. 2024, 15(9): 695.
- Feng H, Yu J, Xu Z, et al. SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via the inhibition of cystine transport in gastric cancer. *eBioMedicine*. 2024, 109: 105375.
- Guo Y, Hu C, Cai K, et al. KRAS inhibitors may prevent colorectal cancer metachronous metastasis by suppressing TGF- β mediated epithelial-mesenchymal transition. *Molecular Medicine Reports*. 2025, 31(1): 1-12.
- Chen J, Zhang Y, Chen X, et al. Raddeanin A Inhibits Colorectal Cancer Growth and Ameliorates Oxaliplatin Resistance Through the WNT/ β -Catenin Signaling Pathway[J]. *Cancer Biotherapy & Radiopharmaceuticals*. 2024

- Liu J, Luo D, Chen X, et al. 4'-Demethylpodophyllotoxin functions as a mechanism-driven therapy by targeting the PI3K-AKT pathway in Colorectal cancer. *Translational Oncology*. 2025, 51: 102199.
- Feng Y, Cao Z, Xu A, et al. Evaluation of toxicity and mutagenicity of oxaliplatin on germ cells in an alternative in vivo model *Caenorhabditis elegans*. *Food and Chemical Toxicology*. 2023: 113902.
- Li D, et al. Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS. *Aging (Albany NY)*. 2021 Jan 20;13(3):4242-4257.
- SIRT7-mediated NRF2 deacetylation promotes antioxidant response and protects against chemodrug-induced liver injury
- Chen W, et al. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. *Cell Death Dis*. 2019 Aug 8;10(8):600.
- Yu Y, Wu T, Zhang X, et al. Regorafenib activates oxidative stress by inhibiting SELENOS and potentiates oxaliplatin-induced cell death in colon cancer cells. *European Journal of Pharmacology*. 2023: 175986.
- Ta LE, et al. Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. *Mol Pain*. 2009 Feb 26;5:9.
- Zhang Z, Ye J, Liu X, et al. Huangqi Guizhi Wuwu decoction alleviates oxaliplatin-induced peripheral neuropathy via the gut-peripheral nerve axis. *Chinese Medicine*. 2023, 18(1): 1-15.
- Feng W Q, Zhang Y C, Gao H, et al. FOXD1 promotes chemotherapy resistance by enhancing cell stemness in colorectal cancer through β -catenin nuclear localization. *Oncology Reports*. 2023, 50(1): 1-14.
- Zhou Y, Yang L, Xiong L, et al. KIF11 is upregulated in colorectal cancer and silencing of it impairs tumor growth and sensitizes colorectal cancer cells to oxaliplatin via p53/GSK3 β signaling[J]. *Journal of Cancer*. 2021, 12(12): 3741.
- Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation[J]. *Journal of chemical information and modeling*. 2019, 59(10): 4374-4382.
- Li J, Lv J, Chen Y, et al. Tumor suppressor circPDE4D inhibits the progression of colorectal cancer and regulates oxaliplatin chemoresistance. *Gene*. 2023: 147323.
- Zhao L, Liu S, Zhang X, et al. Satellite glial cell-secreted exosomes after in-vitro oxaliplatin treatment presents a pro-nociceptive effect for dorsal root ganglion neurons and induce mechanical hypersensitivity in naïve mice. *Molecular and Cellular Neuroscience*. 2023: 103881.
- Yang P, Liu W, Fu R, et al. Cucurbitacin E Chemosensitizes Colorectal Cancer Cells via Mitigating TFAP4/Wnt/ β -Catenin Signaling[J]. *Journal of Agricultural and Food Chemistry*. 2020
- Wang X, Wu F, Wang H, et al. PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation[J]. *Journal of Experimental & Clinical Cancer Research*. 2020, 39(1): 1-15.
- Liu M, Mai J W, Luo D X, et al. NFATc2-dependent Epigenetic Downregulation of the TSC2/Beclin-1 Pathway is Involved in Neuropathic Pain Induced by Oxaliplatin. *Molecular Pain*. 2023: 17448069231158289.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481